Mavenclad caused lasting loss of inflammatory cells in MS
Key Takeaway
Mavenclad caused a lasting drop in a group of immune cells that showed strong signs of inflammation in people with MS.
What They Found
Researchers followed people with relapsing-remitting MS after treatment with cladribine (Mavenclad). One group of B cells (immune cells involved in MS) showed the deepest and most lasting drop. Other B-cell groups returned over time. In a separate comparison, the cells most affected by treatment produced more inflammation-related signals in people with MS than in healthy donors. These findings may help explain Mavenclad’s lasting benefits, but this study did not measure whether those cell changes improved symptoms.
Who Should Care and Why
The study followed people with relapsing-remitting MS who had completed two yearly courses of Mavenclad. It also compared blood cells from untreated people with MS and healthy donors. The comparison helped identify which cells showed stronger signs of inflammation in MS. The treatment follow-up showed that these cells stayed low for a long time. The findings concern immune cell changes, not whether participants had fewer relapses or less disability.
Important Considerations
You should know this study followed 36 treated people for 48 months. A separate comparison included 16 untreated people with MS and 16 healthy donors. You cannot tell from this study whether the lasting cell changes caused better health outcomes.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
1/1/2027
A Korean study found higher levels of one Epstein-Barr virus antibody in people with MS. Learn why t
Read More
1/1/2027
Explore a study linking a gene change to immune cells in spinal fluid in MS, what those cells may sa
Read More
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.